LUCENTIS® (Ranibizumab intravitreal injection)
LUCENTIS® is indicated for the treatment of patients with:
- Neovascular (wet) age-related macular degeneration (wAMD);
- Macular edema following retinal vein occlusion (RVO);
- Diabetic macular edema (DME).
Intravitreal injections of drugs into the cavity of vitreous body such as Lucentis, Gemase and some corticosteroids are particularly effective in diabetic macular edema, edematous form of age-related macular dystrophy of the retina, haemophthalmos, thrombosis of the central retinal vein and its branches.
Antineovascularisation agent
The drug Lucentis, is able to improve vision in patients with the wet form of age-related macular degeneration of the retina (AMD). Lucentis can cure 85% of patients seeking treatment for AMD. It is also used for the treatment of diabetic macular edema (DME), an eye disease that occurs in people with diabetes. Along with good diabetic blood sugar control, Lucentis is an intravitreal injection given by a skilled eye doctor ONLY. It could be given once a month to treat the symptoms of these eye diseases and restore some vision.
